{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ef0ad954320b108b12f7e8d/61befbd76928fc0016193e44?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021? ","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5ef0ad954320b108b12f7e8d/1592831402822-6b3616a700fc4c91f71700e754cfa7cd.jpeg?height=200","description":"<p>During the 63rd ASH Annual Meeting and Exposition, the&nbsp;GvHD&nbsp;Hub&nbsp;was pleased&nbsp;to speak to steering committee member&nbsp;Mohamad&nbsp;Mohty,&nbsp;Hôpital&nbsp;Saint-Antoine, Paris, FR. We asked, What's the latest&nbsp;in treatment of&nbsp;steroid-refractory acute&nbsp;GvHD&nbsp;at ASH 2021?</p><p><br></p><p>In this podcast,&nbsp;Mohty&nbsp;highlights the latest advances in the field of steroid-refractory acute&nbsp;GvHD and emphasizes&nbsp;the importance of&nbsp;prevention, commenting on&nbsp;anti-thymocyte&nbsp;globulin (ATG), allogeneic hematopoietic stem cell transplant (allo-HSCT), and posttransplant&nbsp;cyclophosphamide. Mohty also mentions&nbsp;the&nbsp;HERACLES&nbsp;trial (NCT03225937) and the use of&nbsp;the JAK&nbsp;inhibitor&nbsp;ruxolitinib.&nbsp;</p>","author_name":"Scientific Education Support"}